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Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein
(BCRP)/ABCG2 drug pump
Herman Burger, Hans van Tol, Antonius W. M. Boersma, Marie¨l Brok, Erik A. C. Wiemer, Gerrit Stoter, and Kees Nooter
Imatinib mesylate (STI571), a potent ty-
rosine kinase inhibitor, is successfully
used in the treatment of chronic myelog-
enous leukemia and gastrointestinal stro-
mal tumors. However, the intended
chronic oral administration of imatinib
may lead to development of cellular resis-
tance and subsequent treatment failure.
Indeed, several molecular mechanisms
leading to imatinib resistance have al-
ready been reported, including overex-
pression of the MDR1/ABCB1 drug pump.
We examined whether imatinib is a sub-
strate for the breast cancer resistance
protein (BCRP)/ABCG2 drug pump that is
frequently overexpressed in human tu-
mors. Using a panel of well-defined BCRP-
overexpressing cell lines, we provide the
first evidence that imatinib is a substrate
for BCRP, that it competes with mitox-
antrone for drug export, and that BCRP-
mediated efflux can be reversed by the
fumitremorgin C analog Ko-143. Since
BCRP is highly expressed in the gastroin-
testinal tract, BCRP might not only play a
role in cellular resistance of tumor cells
but also influence the gastrointestinal
absorption of imatinib. (Blood. 2004;104:
2940-2942)
© 2004 by The American Society of Hematology
Introduction
Imatinib mesylate (STI571) selectively inhibits the tyrosine kinase
activity of BCR-ABL, c-KIT, and PDGFR and is successfully used
for treatment of BCR-ABL–dependent chronic myelogenous and
acute lymphoblastic leukemia, and c-KIT–dependent gastrointesti-
nal stromal tumors.1-6 Clinical trials with imatinib in other tumor
types such as glioblastoma and lung and prostate cancer are in
progress.7 However, the intended chronic use of this oral tyrosine
kinase inhibitor over a prolonged time period may support the
development of cellular resistance. Several molecular mechanisms
leading to imatinib resistance have been reported, ranging from
impaired binding of the drug due to mutations, decreased efficacy
due to amplification of the target gene, and decreased imatinib
uptake in the tumor cells due to overexpression of the MDR1/
ABCB1 gene.8-12
Since imatinib is orally administered, systemic imatinib levels
might depend largely on gastrointestinal absorption and metabolic
inactivation and on clearance by intestinal ABC transporters.13,14
Breast cancer resistance protein (BCRP)/ABCG2 is abundantly
expressed in the gut and, based on its cellular localization in the
apical membrane of the small intestine and colon epithelium, it is
very likely that this ABC transporter is involved in active back
transport of drugs entering from the gut, and in that way may play a
significant role in the systemic bioavailability of oral drugs such as
imatinib.15,16 In addition, BCRP expressed in tumor cell types that
are potential targets for imatinib treatment may cause drug
resistance at the level of tumor cells.16 Therefore, we investigated
whether imatinib is a substrate for the BCRP drug pump using a
panel of well-defined BCRP-overexpressing cell lines. We studied
accumulation of 14C-labeled imatinib and show that the level of
intracellular imatinib is significantly decreased in BCRP-overex-
pressing cells, which could be reversed by the addition of the
fumitremorgin C analog Ko-143. Here, we provide for the first time
evidence that imatinib is a substrate for the BCRP efflux pump.
Study design
Reagents and cell lines
Imatinib and [14C]STI571 mesylate were obtained from Novartis (Basel,
Switzerland). Ko-134 was used as a specific BCRP inhibitor.17 Mitox-
antrone and doxorubicin were obtained from Pharmachemie (Haarlem, The
Netherlands). MCF7 (ATCC, HTB-22); MCF7/MR, a mitoxantrone-
resistant and BCRP-overexpressing subline; MCF7/AdVp3000 overexpress-
ing the R482T BCRP variant; HEK293 cells transfected with pcDNA3
(HEK293/Neo); wild-type BCRP/ABCG2-R482R (HEK293/R); BCRP/
ABCG2-R482G (HEK293/G); and BCRP/ABCG2-R482T (HEK293/T)
were used.
Real-time RT-PCR
Relative mRNA expression for BCRP, MRP1, MRP2, and MDR1 was
determined by real-time reverse transcriptase–polymerase chain reaction
(RT-PCR) using an ABI PRISM 7700 (Applied Biosystems, Foster City,
CA) and the comparative cycle threshold (CT) method as described.18
Analysis of protein expression
BCRP protein levels were determined by Western blot analysis using BCRP-
specific monoclonal antibody BXP-21 (1:200) as described previously.19
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Accumulation of intracellular [14C]STI571 mesylate
Cells (106/mL) were exposed to [14C]STI571 (range, 0.1 Ci [3.7 kBq]-
0.001 Ci [0.037 kBq]; 2.14 M-0.021 M imatinib) for 2 hours at 37°C
and then extensively washed with ice-cold phosphate-buffered saline
(PBS). Imatinib accumulation was calculated from the radioactivity
measured in the cell pellet over that retained in the supernatant as
determined by liquid scintillation counting. Relative accumulation
(mean  standard deviation [SD]), based on at least 3 independent
experiments, is expressed as a fraction of that found in parental cells
(% control).
Flow cytometry
Mitoxantrone and doxorubicin accumulation (fluorescence intensity) was
determined by flow cytometry as described previously.20
Results and discussion
To determine whether imatinib is a substrate for the BCRP efflux
pump, we examined 14C-labeled imatinib accumulation in
MCF7/MR and MCF7/AdVp3000, 2 cell lines known to overex-
press BCRP.16 The relative intracellular imatinib accumulation,
measured after a 2-hour exposure to [14C]STI571 in both MCF7/MR
(59.5% 9.5% [mean  SD]) and MCF7/AdVp (3.6% 1.1%)
was significantly lower as compared with MCF7 (Figure 1A). This
decreased accumulation is indicative of BCRP-mediated efflux;
however, in these drug-selected MCF7 sublines other drug transport-
ers may have been activated. Quantitative real-time RT-PCR (data
not shown) and protein data confirmed that only BCRP (Figure 1A,
insert), and not MDR1, MRP1, or MRP2 (data not shown), was
overexpressed in these MCF7 sublines. Although the difference in
imatinib accumulation between MCF7/MR and MCF/AdVp may
be explained by the expression data, it should be noted that
MCF7/MR overexpresses wild-type (wt)–BCRP whereas MCF/
AdVp overexpresses the 482Thr BCRP variant. Notably, mutations
at 482Arg of wt-BCRP have been implicated in substrate specific-
ity.17 Therefore, BCRP-mediated transport of imatinib was studied
in HEK293 cells transfected with BCRP variants, that is, 482Arg
(HEK293/R), 482Gly (HEK293/G), 482Thr (HEK293/T), or empty
vector (HEK293/Neo). Similar to MCF7, overexpression of BCRP
in HEK293 cell lines resulted in a markedly decreased imatinib
uptake (Figure 1B), confirming that imatinib is a substrate for
wt-BCRP and both mutant (mt)–BCRP variants. However, the
existence of small differences in imatinib accumulation between
wt- and mt-BCRP cannot be excluded. Such subtle differences
were also observed for mitoxantrone.21 Regarding BCRP-mediated
imatinib efflux, our data suggest that codon 482 of BCRP does not
play such a pivotal role in substrate specificity as has been reported
for methotrexate (MTX) and doxorubicin.17,22-24 Accordingly, we
found that doxorubicin is not transported by wt-BCRP, whereas a
significant decrease in doxorubicin accumulation (40%) was seen
in both mt-BCRP variants (Figure 1C). Furthermore, we showed
that mitoxantrone is a substrate for both wt- and mt-BCRP (Figure
1D). With respect to this mutational hot-spot at codon 482 of
BCRP, imatinib parallels the substrate specificity pattern of mitox-
antrone and not that of doxorubicin or MTX.17,23,24
Next, we determined whether the decreased imatinib accumula-
tion could be reversed by Ko-143, a specific inhibitor of BCRP-
mediated transport.17 Evidently, Ko-143 could almost completely
restore the decreased imatinib accumulation in cells overexpressing
wt-BCRP (HEK293/R: 1.7-fold increase in the presence of Ko-143,
P  .01 Student t test) as well as in the 2 mt-BCRP variants
(HEK293/G: 4.1-fold increase, P  .001; HEK293/T: 2.1-fold
increase, P  .01), whereas this specific inhibitor had no effect on
the control HEK293/Neo cells (Figure 1E).
Since mitoxantrone is one of the key substrates for BCRP, we
determined whether imatinib is a competitive substrate for the
same binding site. Mitoxantrone accumulation in the BCRP-
positive MCF sublines was clearly increased by addition of 15 M
imatinib as a competitor, whereas accumulation in the BCRP-
negative MCF7 parental line was hardly affected (Figure 2A).
Similar results were found in BCRP-overexpressing HEK293 cells,
that is, mitoxantrone steady-state levels were markedly increased
by the addition of imatinib (Figure 2B). Moreover, mitoxantrone
efflux was almost completely inhibited by 15 M imatinib. These
competition studies suggest that cotreatment of imatinib with other
BCRP substrate drugs may have a significant impact on the oral
bioavailability of these drugs.
It was recently shown that imatinib can potently reverse
BCRP-mediated resistance to topotecan and SN-38 in vitro;
however, in contrast to our results presented here, it was concluded
that imatinib directly inhibits BCRP-mediated transport without
being a competitive substrate.25 The investigators reported that the
Figure 1. Intracellular accumulation of [14C]STI571 mesylate, doxorubicin, and
mitoxantrone. (A) The intracellular [14C]STI571 accumulation (mean  SD) in
BCRP-overexpressing MCF7 sublines and (B) BCRP-transfected HEK293 cells. The
relative accumulation of [14C]STI571, after a 2-hour exposure to this radioactive
compound, is based on the mean of at least 3 independent experiments and is
expressed as a fraction of that found in parental BCRP-negative cells (% control). (C)
Relative accumulation of doxorubicin and (D) mitoxantrone in HEK293 cells,
transfected with pcDNA3 (HEK293/Neo), wt-BCRP (HEK293/R), or mt-BCRP vari-
ants at residue 482 (HEK293/G and HEK293/T). Intracellular accumulation was
measured by flow cytometry. Relative accumulation of these drugs, shown as
fluorescence intensity (peak value) of at least 20 000 events, is shown as fraction
relative to that found in control HEK293/Neo cells (% control). (E) The effect of 200
nM Ko-143 on the steady-state accumulation of [14C]STI571 in the panel of HEK293
cells. HEK293 BCRP variants were preincubated with Ko143 (200 nM) for 1 hour and
then exposed to 14C-labeled imatinib (0.21 M) for an additional 2 hours. Beta-
radiation (dpm) was used as a measure of the intracellular [14C]STI571 accumulation.
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accumulation and subsequent efflux of 14C-labeled imatinib was
similar in cells expressing functional or nonfunctional BCRP. The
apparent discrepancy with our findings may be ascribed to
methodologic differences, among which are substantial dissimi-
larities in incubation time and temperature. Evidently, our
accumulation data (Figure 1A-B) and in particular the results of
the BCRP-specific inhibitor Ko-143 (Figure 1E) are consistent
with the fact that imatinib is a substrate of BCRP. Together, our
results indicate that BCRP can function as an active outward
transport mechanism for imatinib and this drug efflux pump may
therefore play an important role in drug-drug interaction and
cellular resistance to imatinib.
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Figure 2. Effect of imatinib as a competitor for BCRP-mediated efflux of mitoxantrone. (A) Effect of imatinib (15 M) on mitoxantrone steady-state accumulation (3 M) in
MCF7 parental (left panel), MCF7/MR (middle panel), and MCF7/AdVp (right panel). MCF7 sublines were simultaneously incubated for 2 hours with mitoxantrone (3 M), with
or without imatinib as a competitor (1 M-15 M). The fluorescence data of at least 20 000 events per time point are shown and fluorescence intensity (peak signal) of
mitoxantrone is expressed in arbitrary units (au). (B) Mitoxantrone steady-state accumulation in the presence of 15 M imatinib in HEK293 cells. Representative results from 3
independent experiments are shown. Relative accumulation data (mean  SD) are given as a fraction (% control) relative to the accumulation found in HEK293 control cells
without imatinib.
2942 BURGER et al BLOOD, 1 NOVEMBER 2004  VOLUME 104, NUMBER 9
